Jeff Madwed, PhD is currently Executive Director of the JuvRx Division at Juvenescence, a healthcare organization focused on developing products for healthy aging. Jeff is an experienced drug hunter, pharmacologist and translational researcher who has led discovery and early development project teams at Boehringer Ingelheim, Merck Research Labs and Mitsubishi-Tanabe across multiple therapeutic areas. Jeff has a proven track record for building research capabilities, and pipeline targets, all towards the advancing best-in-class and first-in-class therapeutics, Notably, Jeff played a major role in the discovery and development of Flomax (tamsulosin) and Micardis (telmisartan).

 In his current role, Jeff leads two virtual preclinical stage portfolio companies, Souvien Therapeutics and Selah Therapeutics. At Souvien, Jeff leads the effort to create innovative medicines to address neurodegenerative and inflammatory diseases by targeting epigenetic mechanisms. At Selah, Jeff leads a team developing novel ketone-based therapies for treatment of age-related diseases such as heart failure, chronic kidney disease, migraine, epilepsy and others.  

Prior to his career in biopharma, Jeff completed his Ph.D. in Physiology and Biophysics at Harvard; did his post-doctoral work in cardiorenal physiology at St. Luke’s Hospital/Kansas University Medical School in Kansas City, MO, and worked on electrophysiology mapping of the heart to improve diagnosis. 

Jeff loves spending time traveling with his family and friends, stays active by hiking, golfing and running, and gives back his time on efforts to improve community relations.